Update (June 21, 2012):This story was updated to include the fact that MDA funding helped support the phase 1 trial, as well as the preclinical development of RG3039.
Top scientists and clinicians from around the world are discussing the latest research in neuroscience, and the care of individuals with nerve and muscle diseases, at the 2012 annual meeting of the American Academy of Neurology in New Orleans, April 21-28.
The progress of several experimental therapies currently in development for neuromuscular diseases was discussed at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.
Adequate levels of zinc finger protein 1 (ZPR1) appear to be a "protective" modifier of spinal muscular atrophy (SMA), an MDA-supported team of scientists has reported.
Modifiers influence disease onset and severity by changing various biological pathways.
The identification of ZPR1 as a modifier reveals a potential target for therapy development and also sheds light on the mechanisms that drive SMA.
Below are highlights of two recent studies in spinal muscular atrophy (SMA), a disease in which the nerve cells that control muscles (motor neurons) in the spinal cord die, causing progressive weakness in the voluntary muscles.
Destiny has been drawing since age 3. She has served as a local Goodwill Ambassador for several years. Her hobbies include fishing, reading and swimming.
Mathew’s artwork depicts a sunset at Camp Marie in Leonardtown, Maryland, home of the local MDA summer camp. Mathew’s hobbies included music and writing poetry. He collaborated over the Internet with a writer from Wisconsin and together they published a work of poetry called “The Move.”
Russell created his painting at age 15 at an MDA-sponsored children's art workshop. While a student at Lackland Air Force Base High School, he enjoyed playing junior varsity basketball.